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ABSTRACT
A simple method for the preparation of c&-dichloro(1,4,7-triazacyclononane)platinum(ll), c&-Pt(tacn)Cl2
is presented, together with the results of screening the compound against the K-562 (leukemia) and SK-OV-3
(ovarian) human cancer cell lines. While the compound shows no activity against K-562 cells, there is
evidence for some cytotoxicity against SK-OV-3. The compound is much less effective than cisplatin, and its
limited solubility restricts the useable concentration range.
INTRODUCTION
While the matriarchal platinum anti-cancer agent, cisplatin, has been known for 150 years, its efficacy in
the treatment of a variety of types of cancer was only discovered serendipitously by Rosenberg in the 1960’s
/1-3/. Since its approval for clinical use in 1978, it has developed into a $500 M a year industry, and has
proved very successful in the treatment of testicular and ovarian cancer, as well as contributing to the
treatment of lymphomas, head and neck, and bladder cancer/4/. However, the clinical use of cisplatin has
several drawbacks. These include severe nausea and vomiting and severe nephrotoxicity/5/. While these
problems have been ameliorated by aggressive diuresis and the use of anti-emetics, a "second-generation" of
platinum anti-cancer agents were sought/6/. In these platins, chloro- ligands were replaced by more stable
chelating ligands, resulting in complexes that were found to have lower renal toxicity, while retaining anti-
tumour activity /7/. A key example is carboplatin, which causes significantly less nausea, vomiting and
nephrotoxicity than cisplatin, but is as effective in the treatment of ovarian cancer/8/.
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These platins still require intravenous administration, and in the 1990’s a "third generation" of platins
were explored. These are based on platinum(IV) compounds, that, having a d
6 low-spin electronic
configuration, are substitutionally inert. Hence these complexes may be resistant to hydrolysis by gastric
juices, and may be orally viable. One example is JM 216. It is believed that once JM216 enters a cell, native
anti-oxidants, such as cysteine or methionine present in cell proteins reduce the octahedral Pt(IV) complex to
the square-planar Pt(II) form. Thus acetato- ligands are lost and a cisplatin-like molecule is generated in situ.
The evolution of platin chemistry has been thoroughly reviewed periodically/9-11/and the chemistry and
biochemistry of cisplatin and its successors have been elegantly detailed in a recent book/12/.
Our laboratory has been interested in the structure and redox activity of transition metal macrocycles/13/.
We have recently, turned our attention to the investigation of platinum complexes of meso- and rac-
macrocycles bearing pendant carboxylato- arms, to determine whether these macrocycles stabilize
platinum(IV) complexes, that will be substitutionally inert, and that may be reduced by cysteine to the
platinum(II) form/14/. In that study we found that the great thermodynamic stability of the platinum(IV)
complexes, imparted by the "macrocyclic effect"/15/and by the negatively-charged pendant arms induced
disproportionation of the platinum(If) compounds (formed by reduction of the Pt(IV) forms by cysteine),
resulting in the precipitation of platinum(0) metal, free maerocycle and reformation of the platiunum(IV)
complex. Thus these compounds were deemed not to be viable candidates as anti-tumour drugs.
Consequently, we are presently examining the anti-cancer potential of platinum macrocycles where the
propensity for disproportionation is avoided.Hence the present work examines the anti-cancer potential of the
title compound, cis-dichloro-(1,4,7-triazacyclononane)platinum(II), cis-Pt(tacn)CI2.
cis-Pt(tacn)CI2.
The tacn macrocycle is too small to encapsulate a central metal ion, thus no disproportionation is
expected, since the platinum ion is coordinated in an exocyclic fashion. We report here a facile synthesis of
the title compound, together with the results of its screening against two human cancer cell lines, K-562
(leukemia) and SK-OV-3 (ovarian).
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MATERIALS AND METHODS
Potassium tetrachloroplatinate(ll), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, RPMI
1640 medium (without L-glutamine), McCoy’s 5a (without L-glutamine), and cisplatin were obtained from
Sigma. L-Glutamine and fetal bovine serum were obtained from CanSera. Molecular Biology grade DMSO
was obtained from Fisher. 1,4,7-Triazacyclononane (taen) was synthesized by a modified literature method
/16/. Its purity was confirmed by H and C NMR spectrometry. The K-562 cells were generously donated
by Dr. Alastair Cribb. The SK-OV-3 cells were purchased from American Type Culture Collection.
Fourier transform infrared spectra were measured using a Bruker Equinox 55 spectrometer. Solution
NMR spectra were measured using a Bruker Avanee 300MHz spectrometer. Solid state spectra were run at
the Atlantic Regional NMR facility, Dalhousie University. Platinum analyses were carried out using a Varian
SpectrAA-10 atomic absorption spectrometer.
Synthesis
To a stirred, aqueous solution (30 mL) of KzPtCI4 (3. g, 7.5 mmol) was added dropwise, under nitrogen,
a methanolie solution (10 mL) of taen (0.95g, 7.4 retool). The K_PtC14 solution was filtered prior to reaction,
to remove any metallic platinum and KPtCI impurities. The solution was stirred at room temperature for
one hour, during which time a bright orange precipitate formed. The mixture was allowed to stir, in the dark,
overnight and then filtered. The precipitate was washed with cold water, methanol and dried in vacuo. Yield
1.36 g (47 %). Anal. Found: Pt 50.8 % Calcd. for PtC6HNaCI:Pt 49.4 %. IR (KBr cm’): 3489 (NH), 3159
(CH2), 1620 (NH), 1448 (CH2), 1352 (CN), 1129 (CN), 1054 (CN). The aC MAS NMR (solid state) gave a
broad peak at 54.77 ppm.
Solubility of cis-Pt(tacn)Cl2
An excess of solid cis-Pt(tacn)Cl2 was shaken with 9% w/v saline solution and thermostated at 25C in a
recirculating water bath. The saturated solution was filtered and analysed for platinum concentration by
Atomic Absorption spectrometry. The saturated solution was found to contain 704 ppm of platinum, equating
to a molar solubility of 3.6 x 10
"3 tool drrl"3.
In vitro screening
The cell lines tested were K-562 (leukemia) and SK-OV-3 (ovarian). The K-562 cells were grown in
RPMI 1640 culture medium and the SK-OV-3 cells were grown in McCoy’s 5a culture medium. The media
were supplemented with 10% fetal bovine solution and 2% L-glutamine prior to use. The flask containing the
cells was incubated at 37C under an atmosphere of 5.0 % CO2 overnight. The cells were seeded at
concentrations of 40,000, 20,000 and 10,000.cells per well (for I(-562) and 80,000, 40,000 and 20,000 cells
per well (SK-OV-3) for the 24, 48 and 72 hour assays respectively in 96-well microtitre plates. These cell
densities fell within the linear response curve tbr the MTT viability assay.
The platinum compound was dissolved in 9% w/v saline solution prior to use, and filtered through 0.22
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t.tm cellulose acetate filters to produce a sterile solution. The solution was serially diluted with the culture
medium and 20 btL aliquots were added to the wells containing 180 btLof cells so that the final concentrations
in the wells ranged from 0 to 300 laM. This range was limited by the low solubility ofthe compound.
MTT Assay
Cell viability was measured as the activity of the mitochondrial succinate dehydrogenase/17/. To each
cell was added 20 /.tL of 5 mg mL" MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
solution and the plates incubated at 37"C for 2 hours. After addition of 100 laL of biology grade DMSO, with
agitation, the absorbance of the resulting purple formazan solution was measured, using a Molecular Devices
SpecMax 343 diode array spectrometer, running the SoRmax Pro software package. The percentage of viable
cells was calculated by comparing the absorbance of the platinum-treated cells with that of the untreated
controls.
RESULTS AND DISCUSSION
Early studies on the complexation between platinum(II) and tacn /18/ showed the interaction to be
strongly pH dependent. At low pH, the macrocycle was protonated, and the tetrachloroplatinate(II) salt,
[tacnH2](PtC14) precipitated from solution as a pink solid. By raising the pH and adding bromide ion, the cis-
dibromo complex, cis-Pt(tacn)Br= was formed as a yellow product. In a recent study/19/Hambley et al.
isolated the protonated analogue, [cis-Pt(tacnH)Cl2]
+ as the tetrachloroplatinate(II) salt, and reported the
crystal structure. In the present work, we reacted the free macrocyclic triamine with potassium
tetrachloroplatinate in mixed-aqueous medium. Under these conditions, where the solution pH is high, no
protonated macrocycle was produced, and the requisite cis-dichloro product, cis-Pt(tacn)C12 was produced
directly. The low solubility of the complex afforded ready precipitation, while the potassium chloride side-
product remained in solution. The H NMR showed a single peak at 2.23 ppm, suggesting that the compound
is fluxional in solution. Similar fluxional behaviour has been observed for palladium complexes of tacn/20/.
The low solubility of the compound prevented the measurement of a 3C NMR spectrum in solution.
However, a solid state C spectrum was run (at Dalhousie U.). A single broad peak, centred at 54.77 ppm
was obtained. The broadness of the peak may be explained by the nature of the solid sample being
amorphous.
vitro screening
Table shows the percent survival for K-562 cells after exposure to cis-Pt(tacn)CI2 for (a) 24, (b) 48 and
(c) 72 hours, for concentrations of platinum compound ranging from 3 x l0
6 to 3 x l0
"3 mol dm-. The values
presented are the average of at least four sets of replicate measurements. The raw data for all replicates,
including absorbance data for the formazan solutions and the calculated % survivals have been provided as
supplementary information. It is seen that cis-Pt(tacn)Cl2 is ineffective in causing apoptosis in K-562 cells.
64Robez’l L th,,ines and A/eisha. ho’naghan Metal-Based Drugs
Table
Average % cell survival for cytotoxicity assays for K-562 cells treated with cis-Pt(tacn)Cl2,
for a series of concentrations ofthe compound, for 24, 48 and 72 hours.
[cis-Pt(tacn)Cl2] (mol dm"3) 24 hour exposure
blank 100 (100)
1.0 x 10
.8 95 (91)
1.0 x l0
"7 102 (91)
1.0 x 10
.6 107 (97)
1.0 x 104 1.0..0 (8.7.)
values in parentheses refer to cisplatin control results
48 hour exposure %
survival
100 (100)
93 (95)
96 (99)
97 (102)
87 (66)
72 hour exposure
100 (100)
95(104)
103(114)
106(100)
!o4__3)
This is not unexpected, since platinum-based anti cancer drugs have traditionally been found to be effective
against solid tumour cancers /21/. The K-562 leukemia cells are of the soft-tissue type. The control
experiments, using cisplatin, showed a similar lack of apoptosis in K-562 cells, although there is some
indication of effectiveness after 72 hours exposure.
Table 2 shows the percent survival for SK-OV-3 cells after exposure to cis-Pt(tacn)Cl, for (a) 24, (b) 48
and (c) 72 hours, for concentrations of platinum compound ranging from 3 x 10
.6 to 3 x 10s mol dm"s. Little
cell-death was observed after 24 and 48 hours exposure. However, after 72 hours, the average percent
survival for cells exposed to 3 x 10"6, 3 x 104 and 3 x 10
-4 mol dm"s platinum compound was 85, 67 and 77%
respectively. This may be compared to cisplatin, where corresponding survival percentages were 75, 14 and
zero respectively. Thus we may conclude that while cis-Pt(tacn)Cl2 shows some efficacy for apoptosis in
ovarian cells, it is much less effective than cisplatin. This is somewhat surprising, since the complex contains
the well-recognised important "cis-dichloroplatinum(ll)" moiety, analogous to cisplatin. Further, its limited
Table 2
Average % cell survival for cytotoxicity assays for SK-OV-3 cells treated with cis-Pt(tacn)Cl2,
for a series of concentrations of the compound, for 24, 48 and 72 hours.
[cis-Pt(tacn)C12] (mol dm"3)
blank
6.0x 10
-7
6.0x 10
"6
6.0x 104
6.0x 10
-4
24 hour exposure
!00(100)
o3 (85)
102 (80)
110 (73)
119 (67)
values in parentheses refer to cisplatin control results
48 hour exposure
% survival
oo ( oo)
o5 (89
89 (5
98 (2)
98 (0)
72 hour exposure
67(14)
77 (0)
8 (0)
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solubility in saline solution further inhibits its us,. Current work in our laboratory is directed towards
increasing the lypophilicity of platinum-taen complexes by appending aliphatic tails to the macrocycle. This
should serve to increase the bioavailability of the compound. Use of cyclodcxtrins as drug-carriers will
address the solubility problems. This work is ongoing, and will be reported later.
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